Roche posts results for satralizumab TED trial; completes Ocrelizumab SC vs IV MS study

Roche had two Phase III trials advance this week, one with results posted and one with completed status confirmed.

• Roche's "SatraGO-2" trial of satralizumab, an anti-IL-6 receptor monoclonal antibody, in moderate-to-severe thyroid eye disease posted results on 2026-08-12. The study enrolled 127 participants¹ and measured the primary outcome as the percentage of participants in the active TED population who achieved a 2 millimeter or greater reduction in proptosis from baseline to Week 24 in the study eye, without a corresponding worsening in the fellow eye¹.
• Roche's "Ocarina II" trial comparing subcutaneous and intravenous ocrelizumab in multiple sclerosis reached overall completed status, with results first posted 2026-08-11. The study enrolled 236 participants² with either relapsing or primary progressive multiple sclerosis, and the primary outcome was serum ocrelizumab area under the concentration-time curve over the first 12 weeks after SC administration².